Since the early nineties several approaches have been tested to develop safe and effective allergen immunotherapy (AIT) for the treatment of peanut allergy, starting with subcutaneous AIT with aqueous extract,…
Read More
News
Allergen immunotherapy (AIT) still remains the only disease- modifying treatment for immunoglobulin E (IgE)-mediated allergies with proven sustained efficacy upon discontinuation of the treatment, provided it is administered regularly for…
San Diego, June 15th. Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in…
Why did Angany choose to address cat allergy for its first vaccine-candidate? Why not pollens or house dust mites, or a food allergy target? The choice was certainly not…
STOCKHOLM, SWEDEN and QUEBEC CITY, CANADA, NOV. 23, 2021 –Vimian Group has signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany, a Canadian biotechnology…
Food Allergy Center of the Massachusetts General Hospital to Begin Preclinical Trial of Angany’s Vaccine Candidate to Treat Peanut Allergy. QUEBEC CITY, CANADA, NOV. 9, 2021 – Angany Inc.,…
Both Companies will be Present at the 2021 ACAAI Annual Scientific Meeting in New Orleans QUEBEC CITY, CANADA, VAL-DE-REUIL, FRANCE and DECATUR, IL, USA – November 4, 2021 –…
Angany’s choice to confront peanut allergy early on may seem evident. Afterall, not only is it one of the most common food allergies affecting children but it is also one…
QUEBEC CITY, QC CANADA, Val-de-Reuil, Normandy, FRANCE and AUSTIN, TX, March 24th, 2021. Dr Louis-Philippe Vézina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the…
Quebec City, QC, Canada and Val-de-Reuil, Normandy, France, March 10th, 2021 Dr Louis-Philippe Vézina Dr Véronique Gomord (respectively CEO and CSO of Angany), and Pr. Rogier W. Sanders and Dr…
